EPO and Parkinson disease: In the PD model of C57BL/6J mice, intrastriatal infusion of erythropoietin (EPO) demonstrated that the interaction of EPO with the 37 kDa isoform of the EPO receptor significantly improved the outcomes of behavioral testing, in connection with the rescue of dopaminergic markers and decreased neuroinflammation by improving the glycolytic rate and counteracting the redox imbalance in mitochondria [50].